Refine
Has Fulltext
- yes (3)
Is part of the Bibliography
- yes (3)
Document Type
- Journal article (3)
Language
- English (3)
Keywords
- CMV (1)
- CMV-specific cell-mediated immunity (1)
- CMV-specific cellular immunity (1)
- CXCL10 (1)
- IFN-γ ELISpot (1)
- IFNG (1)
- IFN‐γ ELISpot (1)
- QuantiFERON\(^®\)-TB Gold Plus (1)
- RT-qPCR (1)
- T cells (1)
- T-Track\(^®\) TB (1)
- TB (1)
- active TB (1)
- antigen processing and presentation (1)
- cytomegalovirus (1)
- hematopoietic stem cell transplantation (1)
- immune monitoring (1)
- immunomonitoring (1)
- immunosuppression (1)
- in vitro diagnostic (1)
- infection detection (1)
- kidney or renal transplantation (1)
- mRNA (1)
- peptide (1)
- recall antigen (1)
- tuberculosis (1)
Impaired cytomegalovirus (CMV)-specific cell-mediated immunity (CMV-CMI) is a major cause of CMV reactivation and associated complications in solid-organ transplantation. Reliably assessing CMV-CMI is desirable to individually adjust antiviral and immunosuppressive therapy. This study aimed to evaluate the suitability of T-Track® CMV, a novel IFN-γ ELISpot assay based on the stimulation of peripheral blood mononuclear cells with pp65 and IE-I CMV proteins, to monitor CMV-CMI following kidney transplantation. A prospective longitudinal multicenter study was conducted in 86 intermediate-risk renal transplant recipients. CMV-CMI, CMV viral load, and clinical complications were monitored over 6 months post-transplantation. Ninety-five percent and 88–92% ELISpot assays were positive pre- and post-transplantation, respectively. CMV-specific response was reduced following immunosuppressive treatment and increased in patients with graft rejection, indicating the ability of the ELISpot assay to monitor patients' immunosuppressive state. Interestingly, median pp65-specific response was ninefold higher in patients with self-clearing viral load compared to antivirally treated patients prior to first viral load detection (P < 0.001), suggesting that reactivity to pp65 represents a potential immunocompetence marker. Altogether, T-Track® CMV is a highly sensitive IFN-γ ELISpot assay, suitable for the immunomonitoring of CMV-seropositive renal transplant recipients, and with a potential use for the risk assessment of CMV-related clinical complications (ClinicalTrials.gov Identifier: NCT02083042).